How to Get Praluent (Alirocumab) in Connecticut

What Is Praluent and Why Would a Connecticut Doctor Prescribe It?

Praluent is a PCSK9 inhibitor that lowers LDL cholesterol by blocking the protein that degrades LDL receptors on liver cells, allowing those receptors to clear more LDL from the bloodstream. Connecticut physicians prescribe it most often for patients who cannot reach LDL-C goals on maximally tolerated statin therapy, or who have confirmed familial hypercholesterolemia. The FDA approved alirocumab in July 2015 for adults with HeFH or clinical ASCVD requiring additional LDL lowering [1].

LDL-C reductions with alirocumab average 44 to 61 percent depending on background therapy and dose [2]. That magnitude of reduction translates directly into cardiovascular event prevention, as demonstrated in ODYSSEY OUTCOMES (N=18,924), where alirocumab 75 to 150 mg every two weeks reduced the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) versus placebo in patients with recent acute coronary syndrome [3]. All-cause mortality fell by 15 percent (HR 0.85; 95% CI 0.73 to 0.98) in that same trial when the analysis was restricted to patients whose baseline LDL-C exceeded 100 mg/dL [3].

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C of 70 mg/dL or higher, the addition of a PCSK9 inhibitor is reasonable" [4]. Connecticut cardiologists and primary care physicians routinely apply this threshold when deciding whether to initiate alirocumab.

Qualifying Conditions: Who Is Eligible for a Praluent Prescription in CT?

Three clinical scenarios drive the majority of alirocumab prescriptions in Connecticut. First, confirmed or probable HeFH, defined by a Dutch Lipid Clinic Network score of 6 or higher or by genetic testing showing a pathogenic LDLR, APOB, or PCSK9 variant. Second, HoFH in patients aged 18 and older with severely elevated LDL-C. Third, established ASCVD, meaning prior MI, stroke, peripheral arterial disease, or coronary revascularization, where LDL-C remains at or above 70 mg/dL despite high-intensity statin therapy.

Connecticut Medicaid (HUSKY Health) covers alirocumab in both FH and ASCVD categories, contingent on prior authorization [5]. The AHA's 2018 Cholesterol Guideline identifies PCSK9 inhibitors as a "high-value option" when 10-year ASCVD risk exceeds 20 percent and statin-only therapy is insufficient [6].

Patients with statin intolerance documented by two or more statin failures may also qualify under most Connecticut commercial payer policies, even without a prior cardiovascular event. Statin intolerance must be recorded in clinical notes, typically with CPK levels and symptom documentation [7].

How to Get a Praluent Prescription in Connecticut: Step by Step

Getting a Praluent prescription in Connecticut follows a predictable sequence. The first step is a clinical consultation, either in-person or via telehealth, with a licensed Connecticut prescriber.

Step 1. Schedule a qualifying consultation. Connecticut's telehealth statute (Conn. Gen. Stat. § 38a-499b) permits prescribing for established and new patients after a synchronous audio-video visit that meets the standard of care [8]. Telehealth platforms licensed in Connecticut, including cardiologists and internists practicing via video, can initiate alirocumab after reviewing labs and medical history. Patients with a recent lipid panel and cardiology records can often complete this in a single 30-minute telehealth session.

Step 2. Obtain required laboratory work. The prescriber will order or review a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), a comprehensive metabolic panel to assess hepatic function, and creatine kinase if statin myopathy is documented. The ACC recommends a baseline LDL-C be drawn on the patient's current lipid-lowering regimen before adding a PCSK9 inhibitor [4]. Most Connecticut Quest Diagnostics and LabCorp locations can return results within 24 to 48 hours.

Step 3. Receive the prescription and initiate prior authorization. The prescriber or their office submits a prior authorization request to the patient's insurer. Connecticut commercial payers, including Aetna, Cigna, UnitedHealthcare, and Anthem BlueCross BlueShield of CT, each maintain PCSK9-specific PA criteria requiring documented statin use at maximum tolerated dose for at least 4 weeks, a qualifying LDL-C threshold (typically 70 mg/dL or higher for ASCVD, or 100 mg/dL or higher for FH), and confirmed diagnosis codes [9].

Step 4. Specialty pharmacy dispensing. Praluent is a specialty biologic distributed through specialty pharmacies. Major specialty pharmacies operating in Connecticut include CVS Specialty, Walgreens Specialty (Shields), and Accredo. The drug ships cold and arrives within 2 to 5 business days of PA approval. Patients store it at 36 to 46 degrees Fahrenheit; it may be kept at room temperature for up to 30 days if needed [1].

Step 5. Begin injections and schedule follow-up labs. The starting dose is alirocumab 75 mg subcutaneous every two weeks, titrated to 150 mg every two weeks at 4 to 8 weeks if LDL-C response is inadequate. A follow-up fasting lipid panel 4 to 8 weeks after initiation confirms response per ACC/AHA guidance [4].

Telehealth Access to Praluent in Connecticut

Connecticut's telehealth infrastructure allows most of the prescribing process to happen without an office visit. Connecticut law requires audio-video capability for prescribing controlled substances, but alirocumab is not scheduled, so audio-only visits may satisfy certain payers, though video is standard practice [8].

HealthRX-affiliated physicians licensed in Connecticut can complete the intake, review lab results uploaded by the patient, and submit the PA packet electronically. The prescriber's DEA and Connecticut medical license numbers appear on the PA submission; insurers accept telehealth-originated PA requests at the same rate as in-person ones, provided the clinical documentation meets PA criteria [9].

Patients transferring care from another state must ensure their prior Connecticut physician sends records confirming statin intolerance or prior cardiovascular events. Connecticut does not impose a waiting period for telehealth-initiated specialty prescriptions.

The HealthRX Connecticut Praluent Access Framework outlines a three-tier approach based on insurance status. Tier 1 (commercially insured): telehealth consult, PA submission, specialty pharmacy ship within 10 to 14 days. Tier 2 (Connecticut Medicaid/HUSKY): in-person or telehealth consult, HUSKY PA submission with additional documentation of statin trial, specialty pharmacy ship within 14 to 21 days. Tier 3 (uninsured or PA denied): Sanofi's My Praluent patient support program, which can reduce out-of-pocket cost to $0 per month for eligible patients, or 503A compounded alirocumab through a Connecticut-licensed compounding pharmacy pending physician order.

Prior Authorization in Connecticut: What Documentation Is Required

Prior authorization for Praluent in Connecticut is not optional for most payers; it is mandatory. Aetna's 2024 clinical policy bulletin for PCSK9 inhibitors requires: (1) a current LDL-C lab value drawn within the past 12 months, (2) documentation of high-intensity statin therapy at maximum tolerated dose for at least 4 weeks, (3) a diagnosis of HeFH confirmed by genetic testing or clinical criteria, or a diagnosis of clinical ASCVD defined by ICD-10 code, and (4) the prescriber's attestation that the patient is adherent to dietary therapy [9].

UnitedHealthcare's Connecticut formulary requires similar documentation, adding a requirement that the patient has tried and failed ezetimibe 10 mg daily unless contraindicated [10]. Cigna's step-therapy protocol in Connecticut mandates prior use of a high-intensity statin plus ezetimibe before approving a PCSK9 inhibitor [11].

A denied PA is not final. Connecticut's insurance regulations allow an expedited internal appeal within 72 hours for urgent clinical situations and a standard appeal within 30 days for non-urgent cases [12]. Peer-to-peer review calls between the treating physician and the insurer's medical director resolve a meaningful percentage of initial denials. The 2019 IQVIA analysis found that 75 percent of PCSK9 inhibitor PA appeals that reached the peer-to-peer stage were ultimately approved [13].

Praluent Pharmacy Options in Connecticut

Patients filling Praluent in Connecticut use specialty pharmacies rather than standard retail locations. CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty all ship to Connecticut residential addresses and to Connecticut specialty infusion centers [14]. Standard retail pharmacies do not stock alirocumab due to cold-chain and volume considerations.

503A compounding pharmacies licensed by the Connecticut Department of Consumer Protection, Pharmacy and Drug Control division, may prepare patient-specific alirocumab formulations when a prescribing physician documents a clinical rationale for the compounded preparation, such as a specific concentration or delivery device modification [15]. These preparations are not FDA-approved finished products, and the physician must confirm the compounding pharmacy holds a valid Connecticut pharmacy license.

Patients using the Sanofi Praluent savings card may pay as little as $0 per fill at participating specialty pharmacies if their commercial insurance covers the drug [16]. Uninsured patients may apply directly through Sanofi's patient assistance program for free product.

Expected Timeline: From First Appointment to First Dose in Connecticut

The realistic timeline from initial telehealth consult to first injection in Connecticut is 7 to 21 days. The breakdown is approximately as follows: telehealth consultation and lab order on day 1; lab results available by day 2 to 3; PA submission by day 3 to 4; PA decision within 3 to 14 business days depending on the payer; specialty pharmacy order and cold-chain shipment within 2 to 5 business days of approval. Patients with Connecticut Medicaid (HUSKY) should anticipate the longer end of this range because HUSKY PA processing can take up to 14 business days for non-urgent requests [5].

Expedited PA is available when a prescribing physician documents clinical urgency, for example in a patient with recurrent ACS or rapidly progressive carotid disease. In that scenario, Connecticut insurers are required under state law to respond to expedited PA requests within 72 hours [12].

Monitoring After Starting Praluent in Connecticut

Alirocumab does not require hepatic monitoring beyond standard lipid management practice because PCSK9 inhibition does not affect hepatic enzyme production in a clinically meaningful way [2]. The primary monitoring tool is a fasting lipid panel at 4 to 8 weeks after dose initiation or dose adjustment, then every 3 to 12 months once stable, consistent with ACC/AHA Class I recommendations [4].

A secondary LDL-C check confirms whether the 75 mg dose is sufficient or whether up-titration to 150 mg every two weeks is warranted. In ODYSSEY OUTCOMES, patients who achieved LDL-C below 25 mg/dL showed no excess risk of neurocognitive events, hemorrhagic stroke, or new-onset diabetes, addressing a common patient concern [3]. The FDA label notes that injection-site reactions occurred in 7.2 percent of alirocumab-treated patients versus 5.1 percent on placebo; most were mild and self-limited [1].

Connecticut physicians managing alirocumab patients should also revisit statin dose and ezetimibe use at each visit, as combination therapy typically produces greater absolute LDL-C reduction than alirocumab alone [6]. The ACC's Smart Heart program provides Connecticut physicians with a decision support tool for LDL goal setting that integrates PCSK9 inhibitor thresholds [4].

Cost and Coverage for Praluent in Connecticut

The list price for Praluent is approximately $5,850 per year, but very few Connecticut patients pay list price. The structure of coverage depends heavily on the patient's insurance tier [16].

Connecticut Medicaid (HUSKY Health A, B, C, D) covers alirocumab under the preferred drug list with prior authorization and requires documentation of high-intensity statin failure [5]. Commercial payers on the Connecticut exchange vary; Anthem BlueCross BlueShield of CT places alirocumab on Tier 4 or Tier 5, meaning specialty copays apply, but manufacturer savings programs can offset the difference to as low as $0 for commercially insured patients [9]. Medicare Part D coverage depends on the specific plan formulary; the IRA's $2,000 out-of-pocket cap beginning in 2025 meaningfully reduces beneficiary exposure for Connecticut Medicare enrollees [17].

Patients whose insurance denies coverage outright may access alirocumab through Sanofi's Insulins Valyou and Praluent Helps programs, which provide free drug to income-qualifying patients [16]. The eligibility threshold is generally at or below 600 percent of the federal poverty level.

Transferring a Praluent Prescription to Connecticut

Patients relocating to Connecticut from another state can transfer their alirocumab prescription, but several steps are required. The original prescriber must send a complete summary of care including prior PA approval letters, statin trial documentation, and most recent lipid labs to the new Connecticut provider. Connecticut does not automatically honor out-of-state PA approvals; the new Connecticut payer will require a fresh PA submission tied to a Connecticut-licensed prescriber's NPI [12].

Specialty pharmacies with national licenses, such as CVS Specialty and Accredo, can transfer the existing specialty pharmacy relationship to a Connecticut address without requiring a new prescription in most cases, as long as refills remain on the original prescription and the prescribing physician has a Connecticut license or the patient has established care with a Connecticut prescriber. Out-of-state telehealth physicians not licensed in Connecticut cannot write new alirocumab prescriptions for Connecticut residents; Connecticut law requires prescribers to hold an active Connecticut license or a Connecticut telehealth registration [8].